Polycythemia Vera management commonly includes which of the following?

Polycythemia Vera management commonly includes which of the following?

• A. Anticoagulants
• B. Antibiotics
• C. Antivirals
• D. Immunotherapies

Answer: (A)

Preventing thrombosis is the central goal in polycythemia vera management, since the excess red cell mass and increased viscosity raise the risk of arterial and venous clots. The standard approach focuses on lowering thrombotic risk through methods like phlebotomy to keep hematocrit at a safe level and using low-dose aspirin to reduce platelet aggregation. In patients at higher risk (such as older individuals or those with a prior clot), cytoreductive therapy is used to further reduce blood cell production, and anticoagulants may be added to prevent further clot formation, especially after a thrombotic event or when thrombosis risk remains high. The other options—antibiotics, antivirals, and immunotherapies—do not address the clotting risk inherent to PV and are not part of its routine management. Hence, anticoagulants are commonly included in PV management.

Preventing thrombosis is the central goal in polycythemia vera management, since the excess red cell mass and increased viscosity raise the risk of arterial and venous clots. The standard approach focuses on lowering thrombotic risk through methods like phlebotomy to keep hematocrit at a safe level and using low-dose aspirin to reduce platelet aggregation. In patients at higher risk (such as older individuals or those with a prior clot), cytoreductive therapy is used to further reduce blood cell production, and anticoagulants may be added to prevent further clot formation, especially after a thrombotic event or when thrombosis risk remains high. The other options—antibiotics, antivirals, and immunotherapies—do not address the clotting risk inherent to PV and are not part of its routine management. Hence, anticoagulants are commonly included in PV management.